Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis) - Report - MDSpire
Advertisement
Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)
Clinical Report: Efficacy and Safety of Deucravacitinib for Psoriasis
Overview
This multicenter real-world study evaluates the efficacy and safety of deucravacitinib in patients with moderate-to-severe psoriasis, particularly focusing on scalp involvement. Results indicate promising short-term outcomes after 16 weeks, with sustained improvements noted at 32 weeks.
Background
Psoriasis is a chronic inflammatory skin disease affecting millions globally, with significant comorbidities and a substantial impact on quality of life. The management of moderate-to-severe psoriasis often requires systemic therapies, yet access to newer oral agents like deucravacitinib remains limited. Understanding the real-world effectiveness of such treatments, especially in difficult-to-treat areas like the scalp, is crucial for improving patient outcomes.
Data Highlights
111 adult patients were enrolled in the study, with follow-up at 16 and 32 weeks showing significant improvements in scalp psoriasis.
Key Findings
Deucravacitinib demonstrated rapid effectiveness in scalp psoriasis after 16 weeks.
Further improvements were observed at 32 weeks, indicating sustained efficacy.
The safety profile of deucravacitinib was consistent with previous clinical trial data.
Real-world evidence supports the use of deucravacitinib in patients with moderate-to-severe psoriasis.
Patients with scalp involvement showed significant clinical responses, highlighting the need for targeted therapies.
Clinical Implications
Clinicians should consider deucravacitinib as a viable treatment option for patients with moderate-to-severe psoriasis, particularly those with scalp involvement. The favorable safety profile and sustained efficacy observed in this study may enhance treatment strategies in real-world settings.
Conclusion
The findings from this study underscore the potential of deucravacitinib in managing difficult-to-treat psoriasis areas, offering a promising option for patients requiring systemic therapy.
by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Angelo Valerio Marzano, Matteo Megna, Diego Orsini, Lidia Sacchelli, Santo Raffaele Mercuri, Emanuele Trovato, Serena Giacalone, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Simone Ribero, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Carlo G. Carrera, Luca Potestio, Viviana Lora, Andrea Carugno, Federico Bardazzi, Giovanni Paolino, Antonio Costanzo, Alessandra Narcisi, Mario Valenti
